# Bristol Myers Squibb Shares Rise After Two Late-Stage Trials Deliver Results

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/30236
Published: 2026-10-12T11:22:54.000Z
Updated: 2026-10-12T11:22:54.000Z
Section: Business

> The ALOFT-IPF trial of admilparant in adults with idiopathic pulmonary fibrosis met its primary endpoint.

Bristol Myers Squibb shares rose nearly 6% in premarket trading Monday, Oct. 12, after the company posted positive topline results from two Phase 3 trials.

The ALOFT-IPF trial evaluated admilparant in adults with idiopathic pulmonary fibrosis and met its primary endpoint.